Business Context and Reporting Period
This Form 8-K is a current report filed by WellPoint, Inc. (now Elevance Health, Inc.) on January 8, 2013. The filing serves as Regulation FD disclosure regarding upcoming meetings with securities analysts and investors to discuss the company's 2012 financial results and 2013 outlook. The report notes that the company is still completing its year-end 2012 accounting close.
Key Financial Metrics and Guidance
The filing provides preliminary analysis and updated guidance for full-year 2012 and 2013 earnings per share (EPS), distinguishing between GAAP and adjusted figures.
- 2012 GAAP Net Income: Preliminary analysis indicates full-year 2012 GAAP net income will exceed the prior guidance range of $7.37 to $7.47 per share. This increase is primarily attributed to a favorable settlement of a tax matter in the fourth quarter of 2012.
- 2012 Adjusted Net Income: Excluding the tax settlement, Amerigroup acquisition closing costs, and other specific items, adjusted net income is expected to be near the high end or slightly above the prior guidance range of $7.30 to $7.40 per share.
- 2013 Outlook: Management expects relatively stable adjusted net income in 2013 with moderate growth in adjusted net income per share. This outlook includes integration costs related to the Amerigroup acquisition and anticipates a lower share count due to capital deployment.
The filing does not provide specific values for total revenue, operating cash flow, debt levels, or liquidity ratios.
Material Changes and Unusual Items
Several material items influenced the 2012 financial outlook and the reconciliation between GAAP and adjusted earnings:
- Tax Matter Settlement: A favorable settlement of a tax matter in Q4 2012 caused GAAP net income to exceed previous guidance.
- Investment Gains/Losses: The reconciliation includes net realized gains on investments from the first nine months of 2012 ($0.70 per share pre-tax) and other-than-temporary impairment losses ($0.06 per share pre-tax).
- Acquisition Costs: Acquisition and integration costs, including anticipated Q4 2012 costs related to Amerigroup, totaled $0.21 per share pre-tax.
- Litigation Costs: Litigation-related costs were $0.07 per share pre-tax.
Risks and Contingencies
The filing includes a comprehensive Safe Harbor statement identifying numerous risks that could cause actual results to differ from forward-looking statements. Key risks include:
- Regulatory Environment: Increased government participation, regulation, or taxation of health benefits, specifically the impact of the Patient Protection and Affordable Care Act.
- Integration Risks: Challenges in integrating Amerigroup Corporation and 1-800 CONTACTS, Inc., including potential delays, higher costs, or failure to achieve expected synergies.
- Operational and Market Risks: Trends in healthcare costs, utilization rates, ability to secure premium rates, provider contracting, and competitor pricing.
- Legal and Compliance: Litigation, investigations, Medicare/Medicaid compliance, and potential financial penalties related to the Express Scripts, Inc. agreement.
- Financial Risks: Downgrades in financial strength ratings, impairment of intangible assets, and risks associated with substantial outstanding indebtedness.
Investor Verification Checklist
- Verify the final audited 2012 GAAP net income once the year-end accounting close is complete to confirm the impact of the tax settlement.
- Monitor the actual integration progress and cost realization of the Amerigroup acquisition against the 2013 outlook.
- Review subsequent filings for updates on the litigation costs and investment portfolio performance mentioned in the reconciliation.
- Assess the impact of regulatory changes under the Affordable Care Act on premium rates and enrollment trends in upcoming quarterly reports.
- Confirm the execution of capital deployment strategies (share repurchases) to validate the projected lower share count for 2013.